SCHEMBL2222873

SCHEMBL2222873

Cc1ccc(S(=O)(=O)c2ccccc2)cc1NC1CCN(C)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.50
HTR6 P50406 3/20 0.47
ALDH1A1 P00352 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
POLB P06746 2/20 0.46
MAPT P10636 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.44
HTR2A P28223 4/20 0.43
HTR2C P28335 4/20 0.43
KCNH2 Q12809 2/20 0.43
CYP2D6 P10635 2/20 0.43
DRD2 P14416 2/20 0.43
SLC6A2 P23975 2/20 0.43
HTR7 P34969 2/20 0.43
HRH1 P35367 2/20 0.43
ADRA1B P35368 2/20 0.43
SLC6A3 Q01959 2/20 0.43
SLC6A4 P31645 1/20 0.43
CHRM2 P08172 1/20 0.43
CHRM1 P11229 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27887000 0.83 CYP3A4 (0.57) CYP3A4HTR6HTR2AHTR2CCYP2D6
SCHEMBL2170725 0.82 CYP3A4 (0.50) CYP3A4HTR6ALDH1A1SMN1; SMN2POLB
SCHEMBL2223822 0.82 HTR6 (0.41) HTR6ALDH1A1SMN1; SMN2POLBMAPT
SCHEMBL4629472 0.81 VCP (0.46) CYP3A4HTR6HTR2AHTR2CKCNH2
SCHEMBL27886995 0.81 CYP3A4 (0.49) CYP3A4HTR6HTR2AHTR2CCHRM2
SCHEMBL2268905 0.78 HTR6 (0.59) CYP3A4HTR6ALDH1A1MAPTL3MBTL1
SCHEMBL2222879 0.78 NSD2 (0.53) CYP3A4HTR6ALDH1A1POLBHTR2A
SCHEMBL2223943 0.76 CYP3A4 (0.47) CYP3A4HTR6HTR2AHTR2CKCNH2
SCHEMBL16986613 0.76 CYP3A4 (0.49) CYP3A4HTR6ALDH1A1SMN1; SMN2HTR2A
SCHEMBL4630060 0.76 HRH4 (0.42) CYP3A4HTR6HTR2AHTR2CKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2521714-B1 Aromatic sulfone compounds useful in the treatment of central nervous disorders SUVEN LIFE SCIENCES LTD (IN) 2015-08-12 EP claimed
US-20130005709-A1 SULFONE COMPOUNDS AS 5-HT6 RECEPTOR LIGANDS SUVEN LIFE SCIENCES LIMITED (IN) 2013-01-03 US claimed
EP-2521714-A1 SULFONE COMPOUNDS AS 5-HT6 RECEPTOR LIGANDS Suven Life Sciences Limited (IN) 2012-11-14 EP claimed
WO-2011083487-A1 SULFONE COMPOUNDS AS 5-HT6 RECEPTOR LIGANDS SUVEN LIFE SCIENCES LIMITED (IN) 2011-07-14 WO claimed
EP-2521714-B1 Aromatic sulfone compounds useful in the treatment of central nervous disorders SUVEN LIFE SCIENCES LTD (IN) 2015-08-12 EP disclosed
US-9018231-B2 Sulfone compounds as 5-HT6 receptor ligands SUVEN LIFE SCIENCES LIMITED (IN) 2015-04-28 US disclosed
US-20130005709-A1 SULFONE COMPOUNDS AS 5-HT6 RECEPTOR LIGANDS SUVEN LIFE SCIENCES LIMITED (IN) 2013-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130005709-A1 SULFONE COMPOUNDS AS 5-HT6 RECEPTOR LIGANDS HTR6, HTR5A, HTR1A CYP3A4 138/4885HTR6 1/4885ALDH1A1 1669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.